Comparative Pharmacology
Head-to-head clinical analysis: ATACAND versus AZILSARTAN MEDOXOMIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ATACAND versus AZILSARTAN MEDOXOMIL.
ATACAND vs AZILSARTAN MEDOXOMIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Candesartan is an angiotensin II receptor blocker (ARB) that selectively inhibits the binding of angiotensin II to the AT1 receptor, leading to vasodilation, reduced aldosterone secretion, and decreased blood pressure.
Angiotensin II receptor blocker (ARB) that selectively inhibits angiotensin II binding to AT1 receptors, reducing vasoconstriction, aldosterone secretion, and sympathetic activity.
Oral, 8-16 mg once daily initially; titrate to 16-32 mg once daily as monotherapy; maximum 32 mg daily.
40 mg orally once daily. May increase to 80 mg once daily if needed.
None Documented
None Documented
Terminal half-life is approximately 9 hours (range 5-11 hours). In elderly patients, half-life may be prolonged. No accumulation upon repeated dosing.
Clinical Note
moderateAzilsartan medoxomil + Benzydamine
"The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Benzydamine."
Clinical Note
moderateAzilsartan medoxomil + Droxicam
"The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Droxicam."
Clinical Note
moderateAzilsartan medoxomil + Loxoprofen
"The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Loxoprofen."
Clinical Note
moderateTerminal half-life approximately 11 hours; supports once-daily dosing with sustained antihypertensive effect over 24 hours.
Renal (60% unchanged), biliary/fecal (40% as camdhesartan). Approximately 33% of the dose is excreted in urine as unchanged drug, and the remainder as inactive metabolites via bile and feces.
Biliary/fecal (55% unchanged), renal (42% as inactive metabolites, <1% unchanged)
Category C
Category C
Angiotensin II Receptor Blocker
Angiotensin II Receptor Blocker
Azilsartan medoxomil + Clonixin
"The risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Clonixin."